Coronary artery skeleton medicinal coating for preventing restenosis of blood vessel

A technology of drug coating and inner stent, which can be used in drug combination, drug delivery, cardiovascular system diseases, etc., and can solve the problems of accelerated diffusion and increased drug release.

Inactive Publication Date: 2003-07-16
INST OF CHEM CHINESE ACAD OF SCI +1
View PDF0 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

When a biodegradable polymer material is used as a drug carrier, although the release rate of the drug from the carrier will also slow down with the decrease of the drug content, due to the gradual degradation of the

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Example 1: After 0.1 g of poly(lactide-glycolide) random copolymer (PLGA, lactide / glycolide=50 / 50 (mol / mol)) was dissolved in 5 ml of chloroform, 2 mg Paclitaxel, stirred, dissolved evenly and filtered, sprayed onto the surface of 316L stainless steel stent, volatilized the solvent in the air, then repeated spraying once, volatilized the solvent in the air and then desolvated at room temperature under vacuum for 48 hours, paclitaxel in the stent The content is 50μg. After being sterilized by ethylene oxide and implanted into the coronary artery of the dog, no thrombus was found two weeks later.

Embodiment 2

[0027] Example 2: 0.1 g poly(lactide-glycolide-caprolactone) random copolymer (PGLC, lactide / glycolide / caprolactone=45 / 45 / 10 (mol / mol)) After dissolving in 3ml of dichloromethane, add 2mg of paclitaxel, stir, dissolve evenly and filter, dip-coat on the surface of 316L stainless steel stent, volatilize the solvent in the air, and then desolventize at room temperature under vacuum for 48 hours, the The paclitaxel content was 85 μg. After sterilized by ethylene oxide, the canine coronary artery was implanted, and there was no thrombus formation after three weeks.

Embodiment 3

[0028] Example 3: 0.1 g poly(lactide-glycolide-caprolactone) random copolymer (PGLC, lactide / glycolide / caprolactone=45 / 45 / 10 (mol / mol)) After dissolving in 3ml of dichloromethane, add 2mg of paclitaxel, stir, dissolve evenly and filter, dip-coat on the surface of 316L stainless steel stent, volatilize the solvent in the air, then repeat the dip-coating again, volatilize the solvent in the air and then apply it in vacuum The solvent was desolvated at room temperature for 48 hours under conditions, and the content of paclitaxel in the scaffold was 250 μg. After being sterilized by ethylene oxide and implanted into the coronary artery of the dog, no thrombus was found after two months.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A coated medicine layer on the scaffold in arteria coronaria for preventing angiostenosis is prepared through dissolving the aliphatic polylactone and its copolymer is solvent, adding taxusol, stirring while dissolving, filtering, coating on the scaffold, evaporating the solvent, removing the solvent for 48 hr under vacuum, and disinfecting by epoxy ethane.

Description

technical field [0001] The invention relates to a coronary stent drug coating for preventing restenosis of blood vessels, which uses paclitaxel as anti-restenosis drug and biodegradable aliphatic polylactone as drug carrier. Background technique [0002] The popularization and application of coronary artery balloon angioplasty once brought good news to many patients with coronary heart disease, but the biggest defect of this treatment - restenosis of blood vessels has largely limited its curative effect. At present, the mechanism of vascular restenosis has been elucidated, indicating that the occurrence of vascular restenosis is related to multiple factors such as elastic recoil and thrombus formation in the early stage after surgery, smooth muscle migration and hyperplasia in the middle stage, and vascular remodeling in the late stage. To prevent the occurrence of restenosis, a lot of research has been carried out over the years, and treatment methods such as intravascular ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/00A61K31/337A61K47/34A61L31/14A61L33/00A61P9/00
Inventor 王身国盖鲁粤蔡晴陈练贝建中杜洛山
Owner INST OF CHEM CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap